Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Autor: Lucia Nogova, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Martin L. Sos, Sebastian Michels, Rieke N. Fischer, Meike Limburg, Diana S.Y. Abdulla, Thorsten Persigehl, Carsten Kobe, Sabine Merkelbach‐Bruse, Jeremy Franklin, Heiko Backes, Roland Schnell, Dirk Behringer, Britta Kaminsky, Martina Eichstaedt, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Yingying Tian, Lisa Junge, Ahmed A. Suleiman, Sebastian Frechen, Dennis Rokitta, Dongsheng Ouyang, Uwe Fuhr, Reinhard Buettner, Jürgen Wolf

Publikováno v: Cancer Medicine, Vol 9, Iss 14, Pp 4991-5007 (2020)

Abstract Background Treatment of patients with solid tumors and KRAS mutations remains disappointing. One option is the combined inhibition of pathways involved in RAF‐MEK‐ERK and PI3K‐AKT‐mTOR. Methods Patients with relapsed solid tumors wer

Externí odkaz: https://doaj.org/article/04f6918ff70742839866e3f4fa056a57

Supplementary Figures S1-S14 from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer

Autor: Roman K. Thomas, Jürgen Wolf, Lukas C. Heukamp, Reinhard Büttner, Francois Ringeisen, H. Christian Reinhardt, Roland T. Ullrich, Thomas Zander, Daniel Rauh, Steffi Silling, Julie George, Srivari Chandrasekhar, Nagaraju Karre, Prathama S. Mainkar, Alexandra Florin, Martin Peifer, André Richters, Frauke Leenders, Danila Seidel, Marc Bos, Matthias Scheffler, Masyar Gardizi, Dennis Plenker, Joachim Diebold, Oliver Gautschi, Johannes M. Heuckmann, Lynnette Fernandez-Cuesta, Kerstin Albus, Lucia Nogova, Xin Lu, Jakob Schöttle, Felix Dietlein, Florian Malchers

PDF file 34156K, Table of genes from 16 recurrent amplified genomic regions (Figure S1), amplicon focality on TCGA copy number aberrations (Figure S2), hierarchical clustering of CLCGP copy number data (Figure S3), centrality frequencies of common ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaa55b970728bba259689298cf12daa2
https://doi.org/10.1158/2159-8290.22529613

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS)

Autor: Jesus Corral, E. Pereira, Anne-Marie C. Dingemans, Lukas C. Heukamp, Christian Grohé, Helge Bischoff, Enric Carcereny, Anna Kron, Masyar Gardizi, Martin Sebastian, Niki Karachaliou, Bartomeu Massuti, Egbert F. Smit, Martin Reck, Hans-Ulrich Schildhaus, Richard Riedel, Jana Fassunke, Lucia Nogova, Sabine Merkelbach-Bruse, Mariano Provencio, Sebastian Michels, Matthias Scheffler, Sacha I. Rothschild, Enriqueta Felip, Martin Hellmich, A. Insa, Jeremy Franklin, Petra Schmalz, Rafael Rosell, Andreas H. Scheel, Roopika Menon, Jürgen Wolf, Reinhard Büttner, Delvys Rodriguez-Abreu, Diana S.Y. Abdulla, Rieke Fischer, Christian Brandts, Thorsten Persigehl, Meike Limburg

Publikováno v: Journal of Thoracic Oncology, 14(7), 1266-1276. Elsevier Science
Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA

Introduction: ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09274df74058250ad1cc1423ee3f46f1
https://cris.maastrichtuniversity.nl/en/publications/e03b14f3-1f0d-4ea5-8e33-9e6784a04ef1

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

Autor: Matthias Scheffler, Marc Bos, Kerstin Albus, Frank Ueckeroth, Jana Fassunke, Jürgen Wolf, Winfried Randerath, Thomas Zander, Karin Töpelt, Monika Serke, Britta Kaminsky, Walburga Engel-Riedel, Reinhard Büttner, Ulrich Gerigk, Carolin Becker, Michaela Angelika Ihle, Masyar Gardizi, Sabine Merkelbach-Bruse, Sebastian Michels, Erich Stoelben, Lukas C. Heukamp, Carina Heydt, Lucia Nogova, Martin Hellmich, Wolfgang Schulte, Katharina König, Jens Panse, Helen Künstlinger, Yon-Dschun Ko

Publikováno v: Oncotarget
Scopus-Elsevier
Oncotarget 6(2), 1315-1326 (2015). doi:10.18632/oncotarget.2834

Oncotarget 6(2), 1315-1326 (2015). doi:10.18632/oncotarget.2834
Published by Impact Journals LLC, [S.l.]

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7da352d4f268b196b3c55c33dc0c7da3
http://europepmc.org/articles/PMC4359235

MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results

Autor: Delvys Rodriguez Abreu, Helge Bischoff, Vanessa Brandes, Jesus Corral, Niki Karachaliou, E. Pereira, Matthias Scheffler, Jürgen Wolf, Enric Carcereny, Fischer Rieke, Petra Schmalz, Reinhard Buettner, Enriqueta Felip, Meike Thurat, Amelia Insa Molla, Martin Reck, Luis Paz-Ares, Rafael Rosell, Christian Grohé, Jeremy Franklin, Andreas H. Scheel, Masyar Gardizi, Sebastian Michels, Martin Hellmich, Bartomeu Massuti, Lucia Nogova, Martin Sebastian

Publikováno v: Journal of Thoracic Oncology. 12:S379-S380

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46114a6d70888b0f91c3988fde66a920
https://doi.org/10.1016/j.jtho.2016.11.428